JMP ups Boston Scientific to market outperform

Boston Scientific Corp. was upgraded by JMP Securities analyst Robert C. Faulkner to a market outperform rating from market perform. The latest upgrade comes just a day after moving the company up to market perform from market underperform on news of Boston Scientific's offer to acquire Guidant. JMP said it set a deal-dependent price target of $34. Without the deal, the stock is expected to remain flat at $25 to $26. Shares of the Natick, Mass., pharmaceutical company were down 1 cent, or 0.04%, at $26.34 on volume of 16,851,200 shares versus the three-month running average of 5,144,590 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.